182 related articles for article (PubMed ID: 16926812)
1. Rosuvastatin: an independent analysis of risks and benefits.
Zipes DP; Zvaifler NJ; Glassock RJ; Gilman S; Muñoz A; Gogolak V; Gordis L; Dedon PC; Guengerich FP; Wasserman SI; Witztum JL; Wogan GN
MedGenMed; 2006 Jun; 8(2):73. PubMed ID: 16926812
[TBL] [Abstract][Full Text] [Related]
2. Rosuvastatin safety: lessons from the FDA review and post-approval surveillance.
Davidson MH
Expert Opin Drug Saf; 2004 Nov; 3(6):547-57. PubMed ID: 15500414
[TBL] [Abstract][Full Text] [Related]
3. Rosuvastatin: renal disorders and rhabdomyolysis.
Prescrire Int; 2007 Apr; 16(88):68-9. PubMed ID: 17458050
[TBL] [Abstract][Full Text] [Related]
4. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis.
Alsheikh-Ali AA; Ambrose MS; Kuvin JT; Karas RH
Circulation; 2005 Jun; 111(23):3051-7. PubMed ID: 15911706
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of rosuvastatin in treatment of dyslipidemia.
McKenney JM
Am J Health Syst Pharm; 2005 May; 62(10):1033-47. PubMed ID: 15901588
[TBL] [Abstract][Full Text] [Related]
6. The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care.
García-Rodríguez LA; Massó-González EL; Wallander MA; Johansson S
Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):943-52. PubMed ID: 18425988
[TBL] [Abstract][Full Text] [Related]
7. Use of multiple international healthcare databases for the detection of rare drug-associated outcomes: a pharmacoepidemiological programme comparing rosuvastatin with other marketed statins.
García Rodríguez LA; Herings R; Johansson S
Pharmacoepidemiol Drug Saf; 2010 Dec; 19(12):1218-24. PubMed ID: 20922707
[TBL] [Abstract][Full Text] [Related]
8. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.
Kostapanos MS; Milionis HJ; Elisaf MS
Am J Cardiovasc Drugs; 2010; 10(1):11-28. PubMed ID: 20104931
[TBL] [Abstract][Full Text] [Related]
9. Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program.
Shepherd J; Vidt DG; Miller E; Harris S; Blasetto J
Cardiology; 2007; 107(4):433-43. PubMed ID: 17363845
[TBL] [Abstract][Full Text] [Related]
10. The safety of rosuvastatin in comparison with other statins in over 25,000 statin users in the Saskatchewan Health Databases.
García-Rodríguez LA; González-Pérez A; Stang MR; Wallander MA; Johansson S
Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):953-61. PubMed ID: 18425987
[TBL] [Abstract][Full Text] [Related]
11. Results from a rosuvastatin historical cohort study in more than 45,000 Dutch statin users, a PHARMO study.
Goettsch WG; Heintjes EM; Kastelein JJ; Rabelink TJ; Johansson S; Herings RM
Pharmacoepidemiol Drug Saf; 2006 Jul; 15(7):435-43. PubMed ID: 16761304
[TBL] [Abstract][Full Text] [Related]
12. Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases.
Kostapanos MS; Rizos CV; Elisaf MS
Drug Saf; 2014 Jul; 37(7):481-500. PubMed ID: 24788803
[TBL] [Abstract][Full Text] [Related]
13. Rosuvastatin: winner in the statin wars, patients' health notwithstanding.
Wolfe S
BMJ; 2015 Mar; 350():h1388. PubMed ID: 25787130
[No Abstract] [Full Text] [Related]
14. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial.
Saku K; Zhang B; Noda K;
Circ J; 2011; 75(6):1493-505. PubMed ID: 21498906
[TBL] [Abstract][Full Text] [Related]
15. An update on the benefits and risks of rosuvastatin therapy.
Toth PP
Postgrad Med; 2014 Mar; 126(2):7-17. PubMed ID: 24685964
[TBL] [Abstract][Full Text] [Related]
16. Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials.
Wlodarczyk J; Sullivan D; Smith M
Am J Cardiol; 2008 Dec; 102(12):1654-62. PubMed ID: 19064019
[TBL] [Abstract][Full Text] [Related]
17. Myopathy caused by a combination rosuvastatin and fenofibrate.
Dedhia V; Munsi SC
J Assoc Physicians India; 2007 Feb; 55():152-3. PubMed ID: 17571748
[No Abstract] [Full Text] [Related]
18. Safety profile of rosuvastatin: results of a prescription-event monitoring study of 11,680 patients.
Kasliwal R; Wilton LV; Cornelius V; Aurich-Barrera B; Shakir SA
Drug Saf; 2007; 30(2):157-70. PubMed ID: 17253880
[TBL] [Abstract][Full Text] [Related]
19. A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class.
Hoffman KB; Kraus C; Dimbil M; Golomb BA
PLoS One; 2012; 7(8):e42866. PubMed ID: 22936996
[TBL] [Abstract][Full Text] [Related]
20. Rosuvastatin: a risk-benefit assessment for intensive lipid lowering.
Ferdinand KC
Expert Opin Pharmacother; 2005 Sep; 6(11):1897-910. PubMed ID: 16144509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
